Saturday 17 October 2026
Export PFE’s income statement to Excel — free account
Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
29.58
0.14
+0.48%
Follow PFE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
31.68 | 21.44 | 18.31 | 14.81 |
+8 more quarters Free account |
P/S ratio |
2.15 | 2.52 | 2.26 | 2.31 | |
P/FCF ratio |
13.47 | 18.40 | 17.10 | 15.13 | |
P/Operating CF |
164.35 | 61.11 | 26.46 | 31.47 | |
P/B ratio |
1.61 | 1.77 | 1.63 | 1.56 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.96 | 3.34 | 3.08 | 3.05 | |
EV/EBITDA |
9.25 | 10.00 | 9.25 | 9.38 | |
EV/Operating CF |
14.08 | 17.62 | 16.46 | 14.65 | |
EV/FCF |
18.53 | 24.32 | 23.28 | 20.00 | |
Quick Ratio |
0.74 | 0.75 | 0.69 | 0.80 | |
Current Ratio |
1.27 | 1.25 | 1.16 | 1.28 | |
Net Debt/EBITDA |
10.99 | 9.10 | 11.23 | 8.48 | |
Debt/Assets |
31.42% | 31.04% | 31.13% | 29.57% | |
Debt/Equity |
0.74 | 0.71 | 0.75 | 0.66 | |
Asset Turnover |
0.31 | 0.30 | 0.30 | 0.29 | |
Operating CF/Net income |
(3.37) | 0.97 | (3.25) | 1.30 | |
Capex/Depreciation |
(0.33) | (0.27) | (0.50) | (0.36) | |
Research and Development Expense of Revenue |
18.68% | 17.23% | 18.26% | 15.29% | |
Selling, General and Administrative Expense of Revenue |
22.69% | 20.49% | 23.71% | 19.13% | |
Intangible Assets out of Total Assets |
0.59 | 0.60 | 0.60 | 0.58 | |
Share Based Compensation of Revenue |
1.66% | 1.88% | 1.28% | 1.21% | |
Graham Net Nets |
(0.54) | (0.47) | (0.55) | (0.47) | |
Graham Number |
16.02 | 21.64 | 21.62 | 25.17 | |
Earnings Yield |
3.16% | 4.67% | 5.46% | 6.75% | |
Free Cash Flow Yield |
7.42% | 5.43% | 5.85% | 6.61% | |
Revenue per Share |
2.64 | 2.54 | 3.09 | 2.93 | |
Operating CF per Share |
0.15 | 0.46 | 0.94 | 0.81 | |
Capex per Share |
(0.09) | (0.08) | (0.15) | (0.11) | |
Free Cash Flow per Share |
0.05 | 0.38 | 0.79 | 0.70 | |
Cash per Share |
2.05 | 2.30 | 2.39 | 2.64 | |
Shareholders Equity per Share |
15.00 | 15.89 | 15.27 | 16.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.00 | 15.89 | 15.27 | 16.38 | |
Free Cash Flow |
302.00 | 2,179.00 | 4,503.00 | 4,001.00 | |
Working Capital |
8,712.00 | 8,474.00 | 5,914.00 | 10,328.00 | |
Capital Expenditures |
(533.00) | (436.00) | (845.00) | (602.00) | |
Net Current Asset Value |
(74,281.00) | (74,392.00) | (78,487.00) | (68,711.00) | |
EV/EBIT |
13.66 | 14.53 | 13.53 | 13.96 | |
Capex to Sales |
0.04 | 0.03 | 0.05 | 0.04 | |
Price to Operating Income |
9.93 | 10.99 | 9.93 | 10.56 | |
| Other line items | |||||
Average Receivables |
12,284.00 | 12,215.00 | 11,668.50 | 14,355.50 | |
Average Payables |
4,873.50 | 4,873.00 | 5,436.50 | 5,169.00 | |
Average Inventory |
10,807.00 | 10,759.50 | 10,752.50 | 11,594.50 | |
Average Assets |
203,613.00 | 207,823.00 | 210,778.00 | 214,103.50 | |
Average Common Equity |
87,252.00 | 90,520.00 | 87,636.00 | 92,827.00 |
Columns are period end dates